Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I-123]IBZM SPECT study
Autore:
Bernardo, M; Parellada, E; Lomena, F; Catafau, AM; Font, M; Gomez, JC; Lopez-Carrero, C; Gutierrez, F; Pavia, J; Salamero, M;
Indirizzi:
Univ Barcelona, IDIBAPS, Hosp Clin, Dept Psychiat,Serv Psiquiatria, Barcelona 08015, Spain Univ Barcelona Barcelona Spain 08015 Psiquiatria, Barcelona 08015, Spain Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain Univ Barcelona Barcelona Spain na, IDIBAPS, Hosp Clin, Barcelona, Spain Hosp St Pau, Nucl Med Serv, Barcelona, Spain Hosp St Pau Barcelona Spain osp St Pau, Nucl Med Serv, Barcelona, Spain Lilly SA, Dept Clin Res, Madrid, Spain Lilly SA Madrid SpainLilly SA, Dept Clin Res, Madrid, Spain
Titolo Testata:
PSYCHIATRY RESEARCH-NEUROIMAGING
fascicolo: 2, volume: 107, anno: 2001,
pagine: 87 - 97
SICI:
0925-4927(20010825)107:2<87:DOVHDD>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHOTON-EMISSION-TOMOGRAPHY; I-123 IBZM SPECT; ATYPICAL ANTIPSYCHOTIC OLANZAPINE; IN-VIVO; OCCUPANCY; CLOZAPINE; RISPERIDONE; EPIDEPRIDE; PET; NEUROLEPTICS;
Keywords:
psychosis; benzamides; single photon emission computed tomography; olanzapine; D2 dopamine receptor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Bernardo, M Univ Barcelona, IDIBAPS, Hosp Clin, Dept Psychiat,Serv Psiquiatria, Barcelona 08015, Spain Univ Barcelona Barcelona Spain 08015 Barcelona 08015, Spain
Citazione:
M. Bernardo et al., "Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I-123]IBZM SPECT study", PSYCH RES-N, 107(2), 2001, pp. 87-97

Abstract

The aim of this study was to compare in vivo striatal D2 dopamine receptoroccupancy induced by olanzapine and haloperidol in schizophrenic patients using a baseline-endpoint [I-123]IBZM single photon computed emission tomography (SPECT) design. The relationships of striatal D2 receptor occupancy with clinical efficacy and extrapyramidal symptoms (EPS) were also assessed. Twenty-seven inpatients with schizophrenia or schizophreniform. disorder were included in a 4-week prospective, randomized, double-blind, parallel and comparative clinical trial. Thirteen patients were treated with haloperidol (10 mg/day) and 14 with olanzapine (10 mg/day). Ratings of clinical status and EPS were obtained weekly. The percentage of D2 receptor occupancy was estimated by using basal ganglia (striatum)/frontal cortex IBZM uptake ratios obtained from each patient before and after 4 weeks of maintained antipsychotic treatment. Olanzapine led to a mean striatal D2 receptor occupancy of 49% (range 28-69%), which was significantly lower than that induced byhaloperidol (mean 64%, range 46-90%). The baseline-endpoint SPECT design used in this study revealed lower antipsychotic D2 occupancy percentage values than those reported in the literature, using other approaches. The degree of striatal D2 receptor occupancy correlated to the EPS, which predominantly appeared in patients on haloperidol. No relationship was found between the striatal D2 receptor occupancy and clinical improvement. Olanzapine induced a lower striatal D2 occupancy than haloperidol. This low striatal D2 occupancy, together with the lower incidence of EPS in olanzapine-treated patients, contributed to confirm the atypical behavior of this now antipsychotic drug. Nevertheless, conclusions based on SPECT-estimated percentages ofantipsychotic D2 occupancy should be cautious, since the SPECT design could influence the results. In this regard, SPECT studies including baseline and endpoint examinations should be encouraged. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 16:57:58